Effectiveness of Semaglutide in Real-World Weight Management
May 6, 2024
While recent studies confirm semaglutide’s efficacy in significant weight reduction among overweight and obese adults, limited real-world data has confirmed these effects. This retrospective study from Tzoulis et al. evaluated the effectiveness and safety of semaglutide in 40 non-diabetic adults that had a reported average weight of 111.7 kg and BMI of 39.7 kg/m^2. After three months, the median weight loss was 7.4 kg, with 70% of participants achieving over 5% weight loss. At six months, 32% of participants exceeded 15% weight loss. Notably lower response rates were observed in males as well as individuals with psychiatric histories. Adverse health events were reported in 65% of participants, mostly mild and transient, resulting in discontinuation for a singular case. This study underscores semaglutide’s potential in changing the obesity treatment landscape, showing significant weight loss and a good safety profile in a real-life setting.
To read the full publication, click here.
[Source: Cureus, May 2nd, 2024]
